Appointments

ExeVir Bio, a biotech company focused on developing heavy chain-only antibodies to target highly conserved epitopes for broad-spectrum protection against infectious diseases, has announced the appointment of Michael Garrett as its new CEO.

Garrett has an extensive list of qualifications, with over 25 years of experience in biotech, including roles at Flamingo Therapeutics, TCG, Scynexis and BTG plc, where he led ventures and business development. Michael Garrett is set to start his role on 1 December 2024 and will subsequent ly join ExeVir’s board of directors.

Garrett comments on his appointment, “I am honoured to advance ExeVir’s mission of developing new COVID-19 antibody therapeutics to protect the most vulnerable populations, including the immunocompromised and the elderly who may not respond adequately to vaccination, making antibody therapeutics a crucial form of additional protection. I am excited to build on the company’s current pace of innovation, aiming to deliver impactful antibody therapeutics to those who need them most. We are planning our f irst-in-human clinical trial to start in 2025.”

“Michael is an outstanding leader who will drive significant value for ExeVir. Our immediate priority is to rapidly advance XVR013m through clinical trials, emergency use authorisation and conditional approva l, and ultimately, full approva l to combat the ongoing COVID-19 pandemic,” states Dr Jeanne Bolger, chair of the board of Directors. “As we look beyond COVID-19, our highperforming team of scientists is leveraging the VHH platform to discover and develop groundbreaking therapeutics addressing emerging viral threats to human health, a mission with global impact.”

ExeVir leverages its innovative llama-derived antibody (VHH) technolog y to create next-generation treatments, including XVR013m, a COVID-19 antibody currently in development. With the help of its new chief executive officer, ExeVir Bio’s therapy aims to safeguard vulnerable populations, such as the immunocompromised and elderly, from the severe effects of COVID-19, a leading viral respiratory illness.

ExeVir is a clinical-stage biotech company headquartered in Belgium.